Regn Stock Forecast Zacks

For the regeneron pharmaceuticals, inc. 17, 2021 at 10:29 a.m.

Is Regeneron Pharmaceuticals Regn A Worthy Stock Now

And, based on the above valuation metrics, we feel that regn is likely the superior.

Regn stock forecast zacks. Forecast (traded under symbol regn) for one year forward price target at the top of this page, we have presented the average regn forecast for forward target price across the 15 analysts covering regn, as reported in data provided by. Given that regn has a zacks rank #1 (strong buy) and an esp in positive territory, investors might want to consider this stock ahead of earnings. Regn gets ec nod for cocktail, biib's drug approval & more nov.

Get the latest regeneron pharmaceuticals, inc. Regn currently has a forward p/e ratio of 11.67, while incy has a forward p/e of 26.98. Symbol last price market cap % δ 1 yr % δ 5 yr;

Regn is currently sporting a zacks rank of #1 (strong buy). This compares to earnings of $8.36 per share a year ago. The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has.

And, based on the above valuation metrics, we feel that regn is likely the superior. (nasdaq:regn) will announce sales of $4.39 billion for the current fiscal quarter, zacks investment research reports. Stocks with a grades for value and high zacks ranks are among the best value stocks available at any given moment.

Equities analysts forecast that regeneron pharmaceuticals, inc. Since then, regn shares have increased by 36.7% and is now trading at $635.16. A quarter ago, it was expected that this.

This change lagged the s&p 500's daily gain of 0.23%. During the day the stock fluctuated 3.03% from a day low at $640.88 to a day high of $660.28. Regeneron (regn) came out with quarterly earnings of $15.37 per share, beating the zacks consensus estimate of $9.81 per share.

Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model. The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has an improving earnings outlook. Compare regn stock to peers.

Prior to today's trading, shares of the biopharmaceutical. We also note that regn has a peg ratio of 0.64. Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model.

Regeneron pharmaceuticals $630.59 $66b 23.4% 69.5% ilmn. Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model. Et on zacks.com pfizer (pfe) seeks fda's emergency use nod for covid pill

Seven analysts have provided estimates for regeneron pharmaceuticals'. Each stock is a zacks rank #1 strong buy. This quarterly report represents an earnings surprise of 56.68%.

And, based on the above valuation metrics, we feel that regn is likely the superior. Regn investment & stock information. One stock to keep an eye on.

See the report's 7 new picks today. The price has risen in 6 of the last 10 days and is up by 3.35% over the past 2 weeks. The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has an improving earnings outlook.